You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGemifloxacin
Accession NumberDB01155  (APRD00053)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionGemifloxacin is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Structure
Thumb
Synonyms
Factiv
Gemifloxacin mesilate
gemifloxacin mesylate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FactiveTablet320 mg/1OralVansen Pharma Inc.2003-04-04Not applicableUs
FactiveTablet320 mgOralOscient Pharmaceuticals Corporation2006-11-242009-02-19Canada
FactiveTablet320 mg/1OralMerus Labs International Inc.2003-04-04Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIOKR68Y0E4T
CAS number175463-14-6
WeightAverage: 389.3809
Monoisotopic: 389.149932358
Chemical FormulaC18H20FN5O4
InChI KeyZRCVYEYHRGVLOC-HYARGMPZSA-N
InChI
InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
IUPAC Name
7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
SMILES
CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O
Pharmacology
IndicationFor the treatment of bacterial infection caused by susceptible strains such as S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis, S. pneumoniae (including multi-drug resistant strains [MDRSP]), M. pneumoniae, C. pneumoniae, or K. pneumoniae.
Structured Indications
PharmacodynamicsGemifloxacin is a quinolone/fluoroquinolone antibiotic. Gemifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gemifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.
Mechanism of actionThe bactericidal action of gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA gyrase subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43700 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43702 details
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract. The absolute bioavailability averages approximately 71%.
Volume of distribution
  • 1.66 to 12.12 L/kg
Protein binding60-70%
Metabolism

Gemifloxacin is metabolized to a limited extent by the liver. All metabolites formed are minor (<10% of the administered oral dose); the principal ones are N-acetyl gemifloxacin, the E-isomer of gemifloxacin and the carbamyl glucuronide of gemifloxacin.

SubstrateEnzymesProduct
Gemifloxacin
Not Available
N-acetyl gemifloxacinDetails
Route of eliminationGemifloxacin and its metabolites are excreted via dual routes of excretion.Following oral administration of gemifloxacin to healthy subjects, a mean (± SD) of 61 ± 9.5% of the dose was excreted in the feces and 36 ± 9.3% in the urine as unchanged drug and metabolites. The mean (± SD) renal clearance following repeat doses of 320 mg was approximately 11.6 ± 3.9 L/hr (range 4.6-6 L/hr), which indicates active secretion is involved in the renal excretion of gemifloxacin.
Half life7 (± 2) hours
Clearance
  • renal cl=11.6+/- 3.9 L/hr [Healthy subjects receiving repeat doses of 320 mg orally]
ToxicityNot Available
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Gemifloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gemifloxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Gemifloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Gemifloxacin.Experimental, Illicit
AcarboseGemifloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Gemifloxacin.Approved
AcenocoumarolGemifloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Gemifloxacin.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Gemifloxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Gemifloxacin.Approved
AlbiglutideGemifloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Gemifloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Gemifloxacin.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
AlogliptinGemifloxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Gemifloxacin.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Gemifloxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Gemifloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Gemifloxacin.Approved
AmiodaroneGemifloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Gemifloxacin.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Gemifloxacin.Approved
AnagrelideGemifloxacin may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Gemifloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Gemifloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Gemifloxacin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Gemifloxacin.Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
Arsenic trioxideGemifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherGemifloxacin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineGemifloxacin may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Gemifloxacin.Approved
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Gemifloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Gemifloxacin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Gemifloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Gemifloxacin.Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Gemifloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gemifloxacin.Approved, Investigational
BedaquilineGemifloxacin may increase the QTc-prolonging activities of Bedaquiline.Approved
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Gemifloxacin.Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Gemifloxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Gemifloxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
BromfenacBromfenac may increase the neuroexcitatory activities of Gemifloxacin.Approved
BromocriptineGemifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Gemifloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Gemifloxacin.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Gemifloxacin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemifloxacin.Approved
CalciumCalcium can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinGemifloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the neuroexcitatory activities of Gemifloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
CeritinibGemifloxacin may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
ChlorpropamideGemifloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Gemifloxacin.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
CisaprideGemifloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramGemifloxacin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinGemifloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Gemifloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gemifloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Gemifloxacin.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
ClonixinClonixin may increase the neuroexcitatory activities of Gemifloxacin.Approved
ClozapineClozapine may increase the QTc-prolonging activities of Gemifloxacin.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gemifloxacin.Approved
CrizotinibGemifloxacin may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Gemifloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Gemifloxacin.Approved, Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Gemifloxacin.Investigational
DabrafenibDabrafenib may increase the QTc-prolonging activities of Gemifloxacin.Approved
DapagliflozinGemifloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Gemifloxacin.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Gemifloxacin.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Gemifloxacin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Gemifloxacin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Gemifloxacin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Gemifloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Gemifloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Gemifloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gemifloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Gemifloxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Vet Approved
DicoumarolGemifloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Gemifloxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Gemifloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Gemifloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Gemifloxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Gemifloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Gemifloxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Gemifloxacin.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Gemifloxacin.Approved
DisopyramideGemifloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemifloxacin.Approved, Investigational
DofetilideGemifloxacin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Gemifloxacin.Approved
DomperidoneGemifloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Gemifloxacin.Approved
DronedaroneGemifloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved
DulaglutideGemifloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Gemifloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Gemifloxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Gemifloxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Gemifloxacin.Investigational
EliglustatGemifloxacin may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinGemifloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Gemifloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Gemifloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Gemifloxacin.Approved
EribulinEribulin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
EscitalopramGemifloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Gemifloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gemifloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
Ethyl biscoumacetateGemifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Gemifloxacin.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Gemifloxacin.Approved
ExenatideGemifloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Gemifloxacin.Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Gemifloxacin.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Gemifloxacin.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Gemifloxacin.Approved
FenbufenFenbufen may increase the neuroexcitatory activities of Gemifloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved
Ferric CarboxymaltoseThe serum concentration of Gemifloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Gemifloxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Gemifloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
FlecainideGemifloxacin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineFloctafenine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Gemifloxacin.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Gemifloxacin.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gemifloxacin.Approved
FluindioneGemifloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Gemifloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Gemifloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Gemifloxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Gemifloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Gemifloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Gemifloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Gemifloxacin.Approved
FluoxetineGemifloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolGemifloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Gemifloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Gemifloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gemifloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Gemifloxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Gemifloxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Gemifloxacin.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Gemifloxacin.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Gemifloxacin.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Gemifloxacin.Approved
GliclazideGemifloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGemifloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideGemifloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideGemifloxacin may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Gemifloxacin.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Gemifloxacin.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Gemifloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Gemifloxacin.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Gemifloxacin.Approved
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Gemifloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gemifloxacin.Approved, Vet Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Gemifloxacin.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Gemifloxacin.Withdrawn
IbutilideGemifloxacin may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantIcatibant may increase the neuroexcitatory activities of Gemifloxacin.Approved
IloperidoneGemifloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Gemifloxacin.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Gemifloxacin.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Gemifloxacin.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Gemifloxacin.Withdrawn
Insulin AspartGemifloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirGemifloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineGemifloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineGemifloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanGemifloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproGemifloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Gemifloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Gemifloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Gemifloxacin can be decreased when it is combined with Iron saccharate.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Gemifloxacin.Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Gemifloxacin.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Gemifloxacin.Investigational
ItraconazoleItraconazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Gemifloxacin.Approved
KebuzoneKebuzone may increase the neuroexcitatory activities of Gemifloxacin.Experimental
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Gemifloxacin.Approved
LanreotideGemifloxacin may increase the hypoglycemic activities of Lanreotide.Approved
Lanthanum carbonateThe serum concentration of Gemifloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
LeflunomideLeflunomide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
LenvatinibGemifloxacin may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
LiraglutideGemifloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Gemifloxacin.Investigational
LithiumLithium may increase the QTc-prolonging activities of Gemifloxacin.Approved
LopinavirGemifloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamLornoxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved
LumefantrineGemifloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Gemifloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Gemifloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Gemifloxacin.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Gemifloxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Gemifloxacin.Investigational
MecaserminGemifloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Gemifloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Gemifloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Gemifloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Gemifloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Gemifloxacin.Withdrawn
MetforminGemifloxacin may increase the hypoglycemic activities of Metformin.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Gemifloxacin.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Gemifloxacin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gemifloxacin.Approved, Vet Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Gemifloxacin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
MiglitolGemifloxacin may increase the hypoglycemic activities of Miglitol.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Gemifloxacin.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Gemifloxacin.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Gemifloxacin.Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Gemifloxacin.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Gemifloxacin.Approved, Vet Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Gemifloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Gemifloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Gemifloxacin.Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Gemifloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Vet Approved
NateglinideGemifloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Gemifloxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Gemifloxacin.Investigational
NelfinavirNelfinavir may increase the QTc-prolonging activities of Gemifloxacin.Approved
NepafenacNepafenac may increase the neuroexcitatory activities of Gemifloxacin.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Gemifloxacin.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Gemifloxacin.Approved
NilotinibGemifloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Gemifloxacin.Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Gemifloxacin.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Gemifloxacin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
OfloxacinGemifloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Gemifloxacin.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Gemifloxacin.Approved
OlopatadineOlopatadine may increase the neuroexcitatory activities of Gemifloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Gemifloxacin.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Gemifloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Gemifloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Gemifloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Gemifloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Gemifloxacin.Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemifloxacin.Approved, Vet Approved
PaliperidoneGemifloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatGemifloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Gemifloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Gemifloxacin.Approved
PazopanibGemifloxacin may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Gemifloxacin.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Gemifloxacin.Approved
PhenindioneGemifloxacin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonGemifloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gemifloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
PimozideGemifloxacin may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneGemifloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Gemifloxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
PosaconazolePosaconazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational, Vet Approved
PramlintideGemifloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Gemifloxacin.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Gemifloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gemifloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Gemifloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Gemifloxacin.Experimental
PrimaquinePrimaquine may increase the QTc-prolonging activities of Gemifloxacin.Approved
ProbenecidProbenecid may decrease the excretion rate of Gemifloxacin which could result in a higher serum level.Approved
ProcainamideGemifloxacin may increase the QTc-prolonging activities of Procainamide.Approved
PromazinePromazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Gemifloxacin.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Gemifloxacin.Approved
PropafenoneGemifloxacin may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Gemifloxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Gemifloxacin.Investigational
QuetiapineGemifloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Gemifloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineGemifloxacin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineGemifloxacin may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
RepaglinideGemifloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Gemifloxacin.Experimental, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Gemifloxacin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Gemifloxacin.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
RofecoxibRofecoxib may increase the neuroexcitatory activities of Gemifloxacin.Investigational, Withdrawn
RosiglitazoneGemifloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Gemifloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Gemifloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Gemifloxacin.Approved
SaquinavirGemifloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinGemifloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Gemifloxacin.Approved
SevelamerSevelamer can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
SitagliptinGemifloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Gemifloxacin.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
SotalolGemifloxacin may increase the QTc-prolonging activities of Sotalol.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Gemifloxacin.Investigational
Strontium ranelateThe serum concentration of Gemifloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Gemifloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineGemifloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Gemifloxacin.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Gemifloxacin.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Gemifloxacin.Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Withdrawn
TamoxifenTamoxifen may increase the QTc-prolonging activities of Gemifloxacin.Approved
TelavancinGemifloxacin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Gemifloxacin.Approved
TenoxicamTenoxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Gemifloxacin.Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Gemifloxacin.Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Gemifloxacin.Approved
TetrabenazineGemifloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Gemifloxacin.Approved
ThioridazineGemifloxacin may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Gemifloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Gemifloxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Gemifloxacin.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Gemifloxacin.Approved
TolazamideGemifloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideGemifloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Gemifloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Gemifloxacin.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
ToremifeneGemifloxacin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranilastTranilast may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Gemifloxacin.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Gemifloxacin.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Gemifloxacin.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Gemifloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Gemifloxacin.Investigational, Withdrawn
VandetanibGemifloxacin may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Gemifloxacin.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Gemifloxacin.Approved, Investigational
VemurafenibGemifloxacin may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Gemifloxacin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Gemifloxacin.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
WarfarinGemifloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational, Withdrawn
ZiprasidoneGemifloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Gemifloxacin.Withdrawn
ZuclopenthixolGemifloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US5633262
General ReferencesNot Available
External Links
ATC CodesJ01MA15
AHFS Codes
  • 08:12.18
PDB EntriesNot Available
FDA labelDownload (139 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9866
Blood Brain Barrier-0.5099
Caco-2 permeable-0.5644
P-glycoprotein substrateSubstrate0.8404
P-glycoprotein inhibitor INon-inhibitor0.85
P-glycoprotein inhibitor IIInhibitor0.6012
Renal organic cation transporterNon-inhibitor0.5751
CYP450 2C9 substrateNon-substrate0.8462
CYP450 2D6 substrateNon-substrate0.7919
CYP450 3A4 substrateNon-substrate0.5148
CYP450 1A2 substrateNon-inhibitor0.745
CYP450 2C9 inhibitorNon-inhibitor0.6642
CYP450 2D6 inhibitorNon-inhibitor0.809
CYP450 2C19 inhibitorNon-inhibitor0.6581
CYP450 3A4 inhibitorInhibitor0.5418
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7405
Ames testAMES toxic0.6124
CarcinogenicityNon-carcinogens0.7902
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5170 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8366
hERG inhibition (predictor II)Non-inhibitor0.6715
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral320 mg/1
TabletOral320 mg
Prices
Unit descriptionCostUnit
Factive 5 320 mg tablet Box148.08USD box
Factive 320 mg tablet28.48USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5633262 No1995-06-152015-06-15Us
US5776944 No1997-04-042017-04-04Us
US6262071 No1999-09-212019-09-21Us
US6331550 No1999-09-212019-09-21Us
US6340689 No1999-09-142019-09-14Us
US6455540 No1999-09-212019-09-21Us
US6723734 No1998-03-202018-03-20Us
US6803376 No1999-09-212019-09-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityFreely soluble at neutral pH (350 mg/mL at 37 °C, pH 7.0).Not Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.21 mg/mLALOGPS
logP-0.82ALOGPS
logP-0.92ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)5.53ChemAxon
pKa (Strongest Basic)9.53ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area121.35 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity99.74 m3·mol-1ChemAxon
Polarizability39.3 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthyridine carboxylic acids and derivatives. These are compounds containing a naphthyridine moiety, where one of the ring atoms bears a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassNaphthyridine carboxylic acids and derivatives
Direct ParentNaphthyridine carboxylic acids and derivatives
Alternative Parents
Substituents
  • Naphthyridine carboxylic acid
  • Fluoroquinolone
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Dialkylarylamine
  • Aminopyridine
  • Imidolactam
  • Pyridine
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Pyrrolidine
  • Tertiary amine
  • Oxime ether
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Ruiz J, Marco F, Sierra JM, Aguilar L, Garcia-Mendez E, Mensa J, Jimenez De Anta MT, Vila J: In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene. Int J Antimicrob Agents. 2003 Jul;22(1):73-6. [PubMed:12842332 ]
  4. Alkorta M, Gimenez MJ, Vicente D, Aguilar L, Perez-Trallero E: In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Int J Antimicrob Agents. 2005 Feb;25(2):163-7. [PubMed:15664487 ]
  5. Yague G, Morris JE, Pan XS, Gould KA, Fisher LM: Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. [PubMed:11796351 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Alkorta M, Gimenez MJ, Vicente D, Aguilar L, Perez-Trallero E: In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Int J Antimicrob Agents. 2005 Feb;25(2):163-7. [PubMed:15664487 ]
  4. Yague G, Morris JE, Pan XS, Gould KA, Fisher LM: Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. [PubMed:11796351 ]
  5. LaPlante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW: Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother. 2007 Apr;51(4):1315-20. Epub 2007 Feb 12. [PubMed:17296740 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:38